118 related articles for article (PubMed ID: 10551561)
1. FDA advisors recommend approval of taxol for node-positive breast cancer.
Oncologist; 1999; 4(5):430-1. PubMed ID: 10551561
[No Abstract] [Full Text] [Related]
2. [Chemotherapy of ovarian and breast cancer with Taxol].
Dtsch Med Wochenschr; 1996 Dec; 121(50 Suppl):1-12. PubMed ID: 9022362
[No Abstract] [Full Text] [Related]
3. [Adjuvant therapy of breast cancer in the USA].
Bergh J
Lakartidningen; 2000 Feb; 97(8):838. PubMed ID: 10741025
[No Abstract] [Full Text] [Related]
4. NICE approves Taxol for ovarian cancer.
Kmietowicz Z
BMJ; 2000 May; 320(7245):1293. PubMed ID: 10807610
[No Abstract] [Full Text] [Related]
5. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
6. [A case of effective paclitaxel therapy for adriamycin resistant metastatic breast cancer with brain metastases].
Kokufu I; Tanei T; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
Gan To Kagaku Ryoho; 2002 Apr; 29(4):585-8. PubMed ID: 11977543
[TBL] [Abstract][Full Text] [Related]
7. [Evidenced-based medicine and future direction of Taxol].
Hatae M; Nakamura T; Ohnishi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1279-87. PubMed ID: 10945027
[TBL] [Abstract][Full Text] [Related]
8. [Two cases of effective weekly paclitaxel administration and concurrent radiation for metastatic breast cancer].
Kokufu I; Tanei T; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K; Tamaoka K; Hosono M
Gan To Kagaku Ryoho; 2003 Jan; 30(1):111-4. PubMed ID: 12557714
[TBL] [Abstract][Full Text] [Related]
9. FDA approves treatment IND protocol for taxol.
Clin Pharm; 1992 Nov; 11(11):912. PubMed ID: 1361164
[No Abstract] [Full Text] [Related]
10. Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer.
Bryce C; Kennecke H; Chia S; Ragaz J
J Clin Oncol; 2003 Dec; 21(23):4465; author reply 4465-6. PubMed ID: 14645445
[No Abstract] [Full Text] [Related]
11. FDA approves new drug for specific type of advanced breast cancer.
Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
[No Abstract] [Full Text] [Related]
12. Dual-action drug approved for use in advanced breast cancer.
McBride D
ONS Connect; 2007 Jun; 22(6):19. PubMed ID: 17598617
[No Abstract] [Full Text] [Related]
13. Remission of rheumatoid arthritis with taxol in a patient with breast carcinoma.
Yoo WH; Baek HS
J Rheumatol; 2000 Jun; 27(6):1572-3. PubMed ID: 10852303
[No Abstract] [Full Text] [Related]
14. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer.
Harries M; Ellis P; Harper P
J Clin Oncol; 2005 Nov; 23(31):7768-71. PubMed ID: 16204007
[No Abstract] [Full Text] [Related]
15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
16. The Fox Chase Cancer Center and Free University Hospital Investigators' Workshop and Consensus Conference on Paclitaxel. Part 1: Breast Cancer I.
Semin Oncol; 1996 Oct; 23(5 Suppl 11):1-70. PubMed ID: 8966623
[No Abstract] [Full Text] [Related]
17. The emerging role of paclitaxel in breast cancer therapy.
Seidman AD
Clin Cancer Res; 1995 Mar; 1(3):247-56. PubMed ID: 9815979
[No Abstract] [Full Text] [Related]
18. [Paclitaxel, a new anticancer drug].
Jekunen A; Lehtovirta P; Pyrhönen S
Duodecim; 1994; 110(13):1235-40. PubMed ID: 7497933
[No Abstract] [Full Text] [Related]
19. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
20. Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer?
Taghian AG; Assaad SI; Niemierko A; Floyd SR; Powell SN
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):386-91. PubMed ID: 15890579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
